Thermo Fisher Expands Clinical Trial Facility in Suzhou and Enters Strategic Collaboration with Frontier Biotechnologies for HIV Therapy Development

Suzhou, September 27, 2019 /PRNewswire/ --Recently,Thermo Fisher Scientific, a global leader in the field of scientific services (hereinafter referred to as "Thermo Fisher"), has officially announced the completion of facility expansion at its clinical trials manufacturing site in Suzhou, aimed at enhancing its integrated clinical trial supply chain and transportation service network. Additionally, Thermo Fisher has announced a strategic partnership with Frontier Biotechnologies to jointly develop novel therapeutic regimens for the treatment of human immunodeficiency virus (HIV), also known as AIDS.

As the global scaleThe LargestContract Development and Manufacturing Organization (CDMO): Thermo Fisher Scientific offers a comprehensive suite of solutions, including the development of active pharmaceutical ingredients (APIs) and drug products, manufacturing for clinical trials and commercial supply, clinical trial supply chain management, and the development and manufacturing of viral vectors. These capabilities are designed to meet the needs of enterprises of all sizes. In 2019, Thermo Fisher Scientific’s global investments were projected to exceed $270 million, aimed at enhancing pharmaceutical service facilities, recruiting and retaining talent, and helping customers deliver therapies to patients worldwide.High-qualityMedications.

Thermo FisherClinical Trials (Suzhou) PlantExpansion Completed

In response to China’s call to encourage pharmaceutical innovation, the newly expanded Thermo Fisher Scientific Clinical Trials (Suzhou) facility will serve the growing demands of the drug R&D supply chain, focusing on providing high-quality primary and secondary packaging solutions for customers and their patients. The facility will help meet the rising clinical trial needs of Chinese customers, provide development resources for emerging biotechnology companies, and accelerate the market launch of new drug candidates.

Following the expansion, the Suzhou facility covers a total area of nearly 7,000 square meters and will provide comprehensive services including product storage, packaging, and distribution. The expansion adds storage capacity for beta-lactam products, 10℃To 20℃storage capacity and facilities and services such as cold-chain storage, and has also expanded the current 15℃To 25℃，2℃Up to 8℃-20℃Temperature-controlled storage area. With a total investment of nearly $4.4 million, the expanded Suzhou facility will become Thermo Fisher Scientific’s largest clinical trial services manufacturing site in the Asia-Pacific region. This facility is also currently China’sThe Only OneEncapsulation service provider; this packaging method has been widely used in global and local blinded clinical trials. The facility also possesses the capability to print pharmaceutical labels that meet diverse requirements and high standards, thereby enhancing productivity and accelerating time-to-market.

On the opening day, government officials, industry experts, and scholars gathered for a roundtable discussion to share insights and deliberate on trends in drug labeling as well as China’s progress in improving patient outcomes.

Tony Acciarito, President of Thermo Fisher Scientific China, stated, “By expanding the Thermo Fisher Clinical Trials (Suzhou) facility and enhancing our pharmaceutical services capabilities, Thermo Fisher is committed to providing customers with globally leading professional scientific expertise and a world-class integrated service network. Through high-quality assurance and continuously innovative professional scientific services, we help our customers meet the needs of patients worldwide.”

Leon Wyszkowski, President of Thermo Fisher Scientific’s Clinical Trials Business, stated, “The unveiling of the Thermo Fisher Scientific Clinical Trials (Suzhou) facility marks a key milestone in the company’s global strategy to expand its integrated clinical supply chain in China. The facility will focus on quality assurance, cold-chain logistics, and capacity innovation.”

Partnering with Frontier Biologics to Accelerate Innovation in Broadly Neutralizing AntibodiesHIVAntibody Market Launch

Thermo Fisher Scientific Announces Strategic Partnership with Chinese Biopharmaceutical Company Frontier Biotechnologies to Accelerate the Commercialization of 3BNC117, a Novel Broadly Neutralizing Antibody Against HIV, Fulfilling Its Commitment to Helping Customers Deliver to Patients WorldwideHigh-Quality Medicationscommitment.

Thermo Fisher Scientific will become the exclusive drug substance manufacturing partner for 3BNC117 to support its pivotal clinical studies, process validation, and global commercial supply. The product will be manufactured at Thermo Fisher Scientific’s biopharmaceutical facility in St. Louis, Missouri, USA.

“The expansion of the Suzhou plant and the strategic partnership with Frontier Biologics both demonstrate Thermo Fisher Scientific’s ability to help customers address the complex challenges at every stage of the drug development process,” said Michel Lagarde, Executive Vice President and President of Pharmaceutical Services at Thermo Fisher Scientific. “Thermo Fisher Scientific looks forward to supporting customers throughout the entire journey from laboratory to market, helping them make the world healthier.”

This strategic collaboration will leverage Thermo Fisher Scientific’s extensive experience and strong reputation in the development and manufacturing of biopharmaceuticals, while fully utilizing Frontier Biotech’s innovative R&D capabilities in the field of antiretroviral therapy for HIV/AIDS, to accelerate the market launch of 3BNC117. This initiative aims to provide safer and more effective treatment options for people living with HIV, thereby benefiting patients and saving lives.